The highly anticipated trial between Canary Wharf Group and the European Medicines Agency – over whether Brexit “frustrates” the EMA’s lease, allowing it to walk away from its £13m-a-year obligations, has reached court. Here, EG’s deputy legal and professional editor,
Thank you for reading EG
Want to read more? Enjoy a story a week for FREE for one month.
Register
Find Out More